FILTER
FILTERED INTERVIEW RESULTS
Emer Leahy
PRESIDENT & CEO, PSYCHOGENICS
"The main trait we are looking for in partners is access to interesting chemical libraries where, combining good chemistry with our platforms, we can identify novel treatments for neuropsychiatric disorders."
Chris Garabedian
CHAIRMAN AND CEO, XONTOGENY
"People are realizing that our sector may need to be more discerning in deciding which companies are worthy and mature enough to bring to the public markets."
Michael Quirmbach
CEO & PRESIDENT, CORDENPHARMA
"Through our growing network of cGMP facilities across Europe and the US, we aim to continue to translate complex processes and projects at any stage of development into high-value products."
Satya Vadlamani
CHAIRPERSON & MANAGING DIRECTOR, MURLI KRISHNA PHARMA PVT LTD
"We established a dynamic drug delivery systems (DDS) company focused on providing a range of effective solutions to optimize the delivery of pharmaceutical products."
Gil Roth
PRESIDENT, PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION (PBOA)
"The pandemic highlighted the key role that CDMOs play, and we need a voice to drive consensus internally, face regulators, and ensure we have a seat at the table."
Michael Zahra
FORMER PRESIDENT & CEO, DRONE DELIVERY CANADA
"Remote projects may prefer to isolate and limit the number of external individuals visiting as a precaution to avoid the virus spreading, but they need to maintain their supply chain so drones are a perfect unmanned logistics solution."
Marco Mastrodonato
FOUNDER AND CEO, BMG PHARMA
BMG explains the potential of its modified hyaluronic acid technology.
Omar Alessandrini
CEO, Biomedical Pharma
Biomedical Pharma explains the huge scope for its photocatalytic cleaning products.
Vittorio Broccoli & Maud Saillard
EXPORT SALES EXECUTIVES, ERBOZETA
Erbozeta explains how it maintains a high level of growth.
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENT PUBLICATIONS
United States Life Sciences 2024 - Digital Interactive
"Cautious optimism. These two words best describe the state of mind of life sciences executives as we enter the second half of 2024. "
"Cautious optimism. These two words best describe the state of mind of life sciences executives as we enter the second half of 2024. "
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
